Hadas Dvory‐Sobol

机构：Gilead Sciences (United States) · ORCID：0000-0003-0716-2750

发表论文 147 篇 · 总被引 10571 次 · h-index 45

代表论文

• Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection (2022 · New England Journal of Medicine · 被引 312)
• Lenacapavir: a first-in-class HIV-1 capsid inhibitor (2021 · Current Opinion in HIV and AIDS · 被引 149)
• Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial (2022 · The Lancet HIV · 被引 107)
• Efficacy and safety of the novel capsid inhibitor lenacapavir to treat multidrug-resistant HIV: week 52 results of a phase 2/3 trial (2023 · The Lancet HIV · 被引 71)
• Resistance Analyses in Highly Treatment-Experienced People With Human Immunodeficiency Virus (HIV) Treated With the Novel Capsid HIV Inhibitor Lenacapavir (2022 · The Journal of Infectious Diseases · 被引 57)
• Efficacy and Safety of Long-Acting Subcutaneous Lenacapavir in Heavily Treatment-Experienced People with Multidrug-Resistant HIV-1: Week 104 Results of a Phase 2/3 Trial (2024 · Clinical Infectious Diseases · 被引 37)